Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma

This systematic review and meta-analysis synthesized data from early-phase clinical trials involving adults aged 18 years or older with relapsed or refractory diffuse large B-cell lymphoma. The study population comprised 7786 patients receiving experimental agents alone or in combination with CD20-antibodies. The setting encompassed early-phase clinical trials where the primary goal was often to establish safety and preliminary efficacy rather than definitive survival benefits. The comparator was not reported in the source data, which is typical for early-phase trials focusing on novel mechanisms. The review aimed to define contemporary benchmarks for clinicians, investigators and regulators in this therapeutic area.

The primary outcomes assessed were objective response rate and complete response rate. Overall, the meta-analysis reported an objective response rate of 30.5% with a 95% CI of 26.0-35.5. The complete response rate was 14.3% with a 95% CI of 11.5-17.7. These aggregate figures represent the pooled performance of the diverse experimental agents included in the analysis. The data reflects the heterogeneity inherent in early-phase trials where different mechanisms of action are tested simultaneously.

Subgroup analysis by agent class revealed significant variation in efficacy. Cellular therapies demonstrated an objective response rate of 70.0% with a 95% CI of 61.0-77.0 and a complete response rate of 51.0% with a 95% CI of 43.0-59.0. Bispecific antibodies showed an objective response rate of 46.0% with a 95% CI of 38.0-53.0 and a complete response rate of 30.0% with a 95% CI of 24.0-36.0. Antibody-drug conjugates yielded an objective response rate of 40.0% with a 95% CI of 32.0-47.0 and a complete response rate of 18.0% with a 95% CI of 13.0-24.0.

Temporal trends indicated improvement over the study period. The objective response rate for trials conducted between 2000 and 2008 was 16.6% with a 95% CI of 9.0-29.0. In contrast, trials conducted between 2018 and 2025 showed an objective response rate of 36.8% with a 95% CI of 30.0-45.0. This progression suggests that newer agents or combinations have achieved higher response rates in recent years. The complete response rate data for these specific time periods was not reported separately in the source JSON.

Safety and tolerability findings indicated that adverse events occurred in 61.5% of patients with a 95% CI of 54.2-68.3. Discontinuations due to adverse events were reported in 6.0% of patients with a 95% CI of 4.7-7.6. Serious adverse events were not reported in the source data. The review did not provide specific details on the nature of these adverse events or their relationship to the specific agents administered. Tolerability was not reported in the source data.

Methodological limitations include the observational nature of the meta-analysis regarding causality and the heterogeneity of the included trials. The study design relies on early-phase clinical trials which are inherently smaller and less powered for definitive efficacy conclusions compared to phase 3 trials. The lack of reported serious adverse events and specific tolerability data limits the ability to fully assess the risk-benefit profile. The absence of a defined comparator group further restricts the ability to determine relative efficacy.

Clinical implications suggest that these agents offer substantial activity in relapsed or refractory diffuse large B-cell lymphoma. Cellular therapies currently demonstrate the highest response rates but may carry distinct toxicity profiles not detailed here. Bispecific antibodies and antibody-drug conjugates provide intermediate efficacy profiles. Clinicians should consider these options for patients who have exhausted standard therapies. The data supports the use of these agents as part of a broader treatment strategy while monitoring for adverse events.

Several questions remain unanswered regarding long-term survival outcomes and the durability of responses. The review did not report follow-up duration, which is critical for understanding the persistence of benefit. The specific mechanisms driving the high response rates in cellular therapies versus other agents require further investigation. Future research should focus on phase 3 trials to confirm these early findings and establish standard-of-care comparisons. Regulators and investigators must balance the promise of high response rates against the observed high incidence of adverse events.